Moderna (MRNA) Stock: Price, Trend, Options & Financials
Moderna's price regime, relative strength, unusual-options and unusual-volume history, curated-manager ownership and filed fundamentals — joined into one dated stock intelligence page.
What the evidence says now
MRNA closed at $197.00 on Oct 8, 2026. The price is +46.0% from its 50-day average and +174.8% from its 200-day average, which places it in the rules-based “established uptrend” regime. The relative-strength check: over three months the stock returned +188.6%, beating SPY by 186.1%. It remains 7.2% below its 52-week high.
Sources, methodology & freshnessSplit-adjusted OHLCV, end-of-day options chains, SEC 13F filings and EDGAR XBRL company facts · Price/options daily; 13F quarterly; Financials each earnings seasonData as of 2026-10-08 · Open ↓Close ↑
The close is +46.0% from its 50-day average and +174.8% from its 200-day average. Over three months, MRNA returned +188.6% versus +2.5% for SPY.
- vs 50-day
- +46.0%
- vs 200-day
- +174.8%
- From 52W high
- -7.2%
Descriptive, not predictive. “Uptrend” is a rules-based reading of the close and moving averages; it is not a rating, price target or recommendation.
Price & regime
One year of daily price and volume
252 split-adjusted sessions · candles above, share volume below
Unusual options — attention, not intent
MRNA appeared in a UOA top-30 list on 9 of 94 archived scanner sessions: 8 call-side, 5 put-side and 4 on both lists. The latest session did not place it in either top 30. Its larger composite score was 0.32, below the 1.5 “strong” threshold. That is repeated options attention, not proof of bullish trade initiation.
| Recent flag | Call rank | Put rank |
|---|---|---|
| 2026-09-25 | #19 | — |
| 2026-08-27 | #20 | #25 |
| 2026-08-26 | #17 | #29 |
| 2026-08-25 | #18 | #14 |
| 2026-08-24 | #15 | — |
| 2026-08-21 | #4 | — |
| 2026-08-20 | #3 | #6 |
| 2026-08-19 | — | #8 |
| 2026-07-10 | #16 | — |
Latest chain snapshot
2026-10-07Strong-signature cutoff: 1.5. Current OTM volume/OI: 0.251 calls, 0.057 puts.
Curated-manager ownership
1 of the 20 managers in the project's curated 13F set reported a long Moderna position in their latest filing, worth $139M in aggregate at each filing's reported value. This is a focused manager panel, not the complete institutional holder list.
| Fund / manager | Position value | Portfolio | Shares | Quarter change | Report date |
|---|---|---|---|---|---|
Baron Capital Group Ron Baron · MRNA | $139M | 0.21% | 1.99M | — new | 2026-06-30 |
Filed fundamentals — latest snapshot
Go deeper into the filings
The dedicated Financials dashboard carries the complete quarterly and annual income statement, balance sheet and cash-flow history, with derived figures flagged and every XBRL concept disclosed.
Open MRNA Financials →How MRNA trades — the working manual
Moderna develops and commercializes medicines built on its messenger-RNA platform, with respiratory vaccines funding a broader pipeline in oncology, latent and public-health vaccines, and rare diseases. For the stock, commercial vaccine demand and cash use matter alongside probability-weighted clinical and regulatory milestones: one successful program can change the platform's perceived value well before it contributes revenue.
What can move the tape
- 01Commercial demand, market share and seasonality across the COVID and RSV vaccine franchises.
- 02Clinical evidence, regulatory timing and economics for intismeran autogene and the broader oncology pipeline.
- 03Progress across influenza, combination respiratory, latent-virus and rare-disease programs.
- 04Research spending, manufacturing utilization and the pace at which cash and investments fund the pipeline.
What can fool the read
- 01Vaccine recommendations, market acceptance and seasonal demand can change faster than manufacturing commitments.
- 02Topline trial success is not approval; detailed efficacy, safety and regulatory review can change the commercial outcome.
- 03Pipeline value is concentrated in uncertain clinical milestones while the company continues to report operating losses.
- 04Large event-driven moves can overwhelm moving-average and options signals until the price establishes a new range.
Moderna triggered 9 issuer-level flags in the committed 2026-04-01–2026-10-08 archive. The latest was MRNA on 2026-08-25: 2.7× its 30-day average volume while the stock moved +10.3% that session.
Not published yet. The local archive has 1 reported MRNA events—too few for a defensible gap-and-drift study. This missing block is an explicit indexing blocker.
Source map & freshness
| Block | What it uses | Vintage | Raw data |
|---|---|---|---|
| Identity | SEC issuer + primary security mapping | 2026-10-08 | JSON ↓ |
| Price & trend | Split-adjusted daily OHLCV + SPY comparison | 2026-10-08 | CSV ↓ |
| Options | End-of-day chain anomaly ranks | 2026-10-07 | Premium → |
| Ownership | Latest filings from 20 curated 13F managers | 2026-10-08 | Tool → |
| Financials | SEC EDGAR XBRL company facts | 2026-08-27 | JSON ↓ |
| Joined profile | The exact contract rendered by this page | 2026-10-08 | JSON ↓ |
MRNA stock questions
Is MRNA stock in an uptrend?+
MRNA is classified in the “established uptrend” regime as of 2026-10-08: the close is +46.0% from its 50-day average and +174.8% from its 200-day average. This describes the current tape. It is not a forecast.
What does unusual options activity in MRNA mean?+
Moderna's OTM option chain produced an outlier relative to the scanner universe on at least one archived session. Call-side and put-side labels identify which book produced the signature; end-of-day chain data does not identify buyers, sellers, institutions or spread legs.
Are the MRNA 13F holdings current?+
No. 13F filings are delayed quarter-end snapshots and cover only the curated managers in this project. They are useful for documented ownership changes, not real-time positioning or complete institutional ownership.
Where are MRNA's income statement and cash flow?+
The dedicated MRNA Financials page contains the full quarterly and annual income statement, balance sheet and cash-flow history parsed from SEC EDGAR XBRL. This stock page carries only the latest filed snapshot.
Why is there no MRNA earnings-move base rate yet?+
The committed earnings archive does not yet contain enough reported events for a defensible company-level reaction study. The page leaves that block unpublished instead of presenting a tiny sample as a reliable base rate.